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Background:Multidisciplinary team (MDT) approach is amajor
requirement to guarantee a fair access to treatment to heteroge-
neous patients with liver neoplasms and to improve the quality
of care provided. This work retrospectively analyzes the impact of
MDT experience at our tertiary center.
Methods: Between 2011 and 2016, 490 consecutive patients
with a liver mass were discussed at standardized meetings involv-
ing hepatologists, radiologists, surgeons, pathologists, oncologists.
Patients with HCC were assigned a BCLC stage, treated accordingly
BCLC recommendation whenever possible and followed-up as per
AASLD/EASL guidelines (median f-up: 26 months).
Results:Outof490patients, 70%hadaHCCdiagnosis, 5%cholan-
giocarcinoma or metastasis and 25% benign liver nodules. Among
341 HCC patients, 55% were BCLC 0/A, 29% BCLC B and 15% BCLC
C. Of them, 80% received treatment after the first MDT discus-
sion. Patients with BCLC B stage had significantly more treatments
(2.5±0.9 treatments per patient), compared to BCLC 0/A (1.3±0.1)
and to BCLC C (1.2±0.5, both p<0.05). First-line BCLC recommen-
dations for therapy were followed in 67%, 59%, 32% of cases for
BCLC 0/A, B, C respectively. In 274 HCC patients managed until
February 2015 (median f-up: 30 months), median survival from
first MDT discussion was 37 months. Main predictors of outcomes
were BCLC stage (5-years survival in BCLC 0/A 54%, B 21%, C 23%,
p<0.0001), CHILD score (5-years survival CHILD A 42%, B 20%, C 0%,
p<0.0001) and first treatment applied (survival at 5 years from
OLT 90%, resection 49%, ablation 40%, TACE 28%, sorafenib 15%,
p<0.0001)
Conclusions: A MDT approach to HCC patients allowed a ratio-
nal revision of treatments suggested by BCLC recommendations in
30% to 70% of cases; this discrepancy did not affect survival out-
comes, indicating that the difficulties related to the applicability of
the current guidelines in the clinical practice could be overcome by
a MDT approach.
http://dx.doi.org/10.1016/j.dld.2017.01.040
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Introduction: Sympathetic overactivity and generation of per-
oxidant molecules are crucial in liver fibrogenesis and functional
renal failure of advanced cirrhosis. Renalase (REN), 38kDa amine
oxidase with just 13% aminoacid identity with monoamine oxidase
A, is secreted into the blood and clears plasma from excess cat-
echolamines. Isomers of -NAD(P)H are also substrates for tissue
REN, a reaction leading to H2O2 and -NAD(P)+ production in liver
and kidney.
Aims: To study plasma and tissue content and function of REN
in experimental preascitic and ascitic cirrhosis.
Methods: In normal rats (group G1), rats with CCl4-dependent
liver cirrhosis without ascites (G2) and with ascites (G3) we eval-
uated: REN levels and activity in plasma, liver and kidney; REN
gene transcription and immunohistochemical localization in both
organs; liver histology and matrix deposition, hormonal status and
kidney function.
Results: In plasma, mature (38kDa) REN and REN activity, well
detected in normal rats, were virtually absent in rats with com-
pensated or ascitic cirrhosis (P<0.01 vs. G1). In G2 and G3 rats, but
not in G1, we found large amount of enzymatically active high-
molecular weight (78kDa) REN and very little 38kDa protein in
hepatocytes of regenerative nodules of the cirrhotic liver and in
kidney tubules. RT-PCR confirmed higher levels of REN gene tran-
scription in both liver and kidney of G2-3 (P<0.03 vs. G1). Ratswith
preascitic liver damage showed increased plasma catecholamines,
normal renin-angiotensin system activation and subtle sodium
retention, while ascitic rats had both secondary aldosteronism and
increased adrenergic activation.
Conclusions: Active 78kDa REN accumulates in diseased liver
and kidney and generates H2O2 and other pro-oxidant molecules,
but release of mature (38kDa) REN into the circulation is almost
absent, leading to increased levels of catecholamines and early
sodium retention in preascites.
http://dx.doi.org/10.1016/j.dld.2017.01.041
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Introduction: Activation of both Kupffer cells and hepatic stel-
late cells (HSCs) plays a fundamental role in fibrosis process.
Heparanase (HPSE) is the only mammalian endoglucuronidase
capable of cleaving heparan sulfate (HS) chains of HS proteogly-
cans. The involvement of HPSE in chronic liver disease has not been
demonstrated so far.
